Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Risk Factors Identified in TBI for Early Posttraumatic Seizures, Posttraumatic Epilepsy
April 20th 2022Outcomes in TBI admission survivors at 24 months—including mortality, development of posttraumatic epilepsy, and use of antiseizure medications—were poorer for cases with early posttraumatic seizures after adjustment for confounders.
NeuroVoices: Neal Hermanowicz, MD, on Isolation’s Impact on Patient Burden in Parkinson Disease
April 20th 2022The neurologist at Christus St Vincent Health System discussed a recently conducted survey on the effects of social isolation and the need to keep patients with Parkinson disease socially connected.
Several Acupuncture Therapies Improve Sleep Quality Scores in Primary Insomnia
April 19th 2022Investigators found no serious AEs related to acupuncture in all 22 studies that reported on it, consisting unanimously with findings in previous studies. Acupoints catgut embedding, auricular acupuncture plus manual acupuncture, and electroacupuncture plus acupoint application showed the most promise.
ACD Score Proves Valuable in Estimating Long-Term Survival in Status Epilepticus
April 14th 2022New neurological deficits were a predictor of long-term survival regardless of the status epilepticus cause and were associated with a 5-fold increase in the odds of death at 2 years after status epilepticus diagnosis.
Siponimod Reduces Brain Tissue Damage in Secondary Progressive MS, Post Hoc Analysis Suggests
April 14th 2022Over 24 months, treatment with siponimod (Mayzent; Novartis) was associated with improvements in brain tissue integrity and myelination within newly formed normalized magnetization transfer ratio lesions.
Multilevel Impact Fenfluramine’s Approval Brings to Lennox-Gastaut Syndrome
April 14th 2022As a primary investigator for fenfluramine’s pivotal phase 3 program, Kelly Knupp, MD, MSCS, FAES, provided insight on new results presented at AAN 2022, as well as the positive ripple effect its recent approval brings to patients with Lennox-Gastaut syndrome.
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis
April 13th 2022In addition to demonstrating significant differences in slowing functional decline, those on gamma sensory stimulation also demonstrated a significant reduction in brain atrophy relative to the sham group in the OVERTURE study.
NeuroVoices: Elia Pestana-Knight, MD, on the Importance of Ganaxolone’s Approval in CDD
April 6th 2022The pediatric epileptologist at Cleveland Clinic’s Epilepsy Center discussed data presented at AAN 2022 on the use of ganaxolone in CDD, as well as how its recent approval sets the stage for the future.